GlassScriptPhysician profile
Xiaoxiao Wang
NPI 1346089141
$5,830.52
in general payments reported to CMS, 2019-2025
38 companies · $4,345 in 2025
The $4,345 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,486 · 2025: $4,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,236 · Education: $595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,235.74 |
| Education | $594.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,006.19 | 2024-2025 | Rybrevant, Carvykti, Erleada |
| Astrazeneca Pharmaceuticals LP | $906.93 | 2024-2025 | Enhertu, Tagrisso, Calquence |
| Incyte Corporation | $420.40 | 2024-2025 | Jakafi, Jakafi |
| Array Biopharma INC | $396.11 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Merck Sharp & Dohme LLC | $231.69 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $225.59 | 2025 | Vyloy |
| Abbvie INC. | $217.05 | 2024-2025 | |
| Lilly USA, LLC | $210.65 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $207.75 | 2024-2025 | Opdualag, Opdivo |
| Sun Pharmaceutical Industries INC. | $204.94 | 2024-2025 | |
| Eisai INC. | $163.53 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $144.63 | 2024-2025 | Onivyde, Somatuline Depot |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.72 | 2024-2025 | Gilotrif |
| Takeda Pharmaceuticals U.S.A., INC. | $126.73 | 2024-2025 | Iclusig, Fruzaqla, Ninlaro |
| Tersera Therapeutics LLC | $109.54 | 2025 | Zoladex |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $99.99 | 2025 | |
| Jazz Pharmaceuticals INC. | $98.99 | 2025 | |
| Gilead Sciences, INC. | $89.88 | 2025 | Trodelvy |
| Sumitomo Pharma America, INC. | $87.42 | 2024-2025 | Orgovyx |
| Exelixis INC. | $82.96 | 2024-2025 | Cabometyx |
| Beigene USA, INC. | $64.41 | 2024-2025 | Tevimbra |
| Agios Pharmaceuticals, INC. | $60.73 | 2025 | Pyrukynd |
| Emd Serono, INC. | $55.74 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.32 | 2025 | |
| Genentech USA, INC. | $52.65 | 2025 | Venclexta |
| Novocure INC. | $44.95 | 2025 | Optune Lua (Novottf-200t), Optune Gio |
| Legend Biotech USA INC. | $44.03 | 2024-2025 | Carvykti |
| Helsinn Therapeutics (U.S.), INC. | $42.67 | 2024-2025 | Akynzeo |
| Stemline Therapeutics INC. | $34.02 | 2025 | Orserdu |
| Daiichi Sankyo INC. | $28.80 | 2025 | Enhertu |
| Celgene Corporation | $28.00 | 2024 | Opdualag |
| Pfizer INC. | $25.48 | 2025 | |
| Rigel Pharmaceuticals, INC. | $25.39 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Pharmaessentia USA Corporation | $25.02 | 2024 | Besremi |
| Kyowa Kirin, INC. | $23.28 | 2025 | |
| Azurity Pharmaceuticals, INC. | $22.25 | 2025 | Danziten |
| Amgen INC. | $18.08 | 2025 | Lumakras, Imdelltra (Amg757) |
| Adc Therapeutics America, INC. | $15.01 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaoxiao Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.